Who Owns AngioDynamics Company?

AngioDynamics Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns AngioDynamics?

Understanding AngioDynamics' ownership is key to grasping its strategic path and market standing. A significant shift occurred when it spun off from E-Z-EM, Inc., leading to its IPO in May 2004. This transition made it an independent, publicly traded company.

AngioDynamics, founded in 1988, focuses on minimally invasive medical devices. Its journey from a division of E-Z-EM, Inc. to an independent entity has reshaped its shareholder base.

As of July 2025, AngioDynamics, with a market capitalization of approximately $0.37 billion USD, is a notable player in the medical instruments sector. Its product portfolio includes solutions for peripheral vascular disease and oncology, such as those analyzed in the AngioDynamics BCG Matrix. The company employs around 1,400 individuals globally.

AngioDynamics' journey began in 1988 as a research and development initiative within E-Z-EM, Inc. It was established by Eamonn P. Hobbs and Howard S. Stern, aiming to innovate in medical plastics for minimally invasive procedures.

Founding Visionaries

Eamonn P. Hobbs, with a background in plastics engineering and biomaterials, and Howard S. Stern, a co-founder of E-Z-EM, Inc., were the driving forces behind AngioDynamics' inception.

Early Structure

Initially operating as a wholly-owned subsidiary named A.D., Inc. from 1992, the company later rebranded to AngioDynamics, Inc. in 1996.

Parent Company Support

Funding and capital for AngioDynamics during its formative years were provided by its parent company, E-Z-EM, Inc.

Product Development Focus

The founders concentrated on developing key products for interventional radiology, including the Schon Acute Hemodialysis Catheter.

Leadership Transition

Howard S. Stern retired from his chairman roles at both E-Z-EM and AngioDynamics in February 2004, shortly before AngioDynamics' public spin-off.

Shareholder Information

Specific details regarding the initial equity split between the founders or early shareholding percentages are not publicly available.

The early days of AngioDynamics were characterized by its status as a subsidiary of E-Z-EM, Inc., with its strategic direction and product development heavily influenced by its parent company. The focus on creating specialized medical devices for minimally invasive procedures laid the groundwork for its future growth. Understanding the Marketing Strategy of AngioDynamics provides further insight into how these early product developments were brought to market.

AngioDynamics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

AngioDynamics' journey as a public entity began with its Initial Public Offering (IPO) in May 2004, listing on the Nasdaq under the ticker 'ANGO'. This event marked a significant shift, offering 1,950,000 shares at $11.00 each and raising approximately $70 million. This IPO established AngioDynamics as a distinct, publicly traded company, setting the stage for its subsequent ownership evolution.

Following its IPO, AngioDynamics has seen its ownership predominantly held by institutional investors, reflecting substantial interest from large financial entities. As of July 2025, these institutions collectively manage approximately 89.43% of the company's outstanding shares. Among the most significant institutional stakeholders are BlackRock, Inc., holding around 11% of shares, and Systematic Financial Management LP with 5.9%. The Vanguard Group, Inc. also maintains a notable stake of 5.6%. Other key institutional players include Dimensional Fund Advisors, L.P., Geode Capital Management, L.L.C., and Point72 Asset Management, L.P. Furthermore, Millennium Management LLC and its affiliates disclosed a passive stake of approximately 5.2-5.3% as of July 16, 2025, representing between 2.12 million and 2.15 million common shares. Bastion Asset Management Inc. also increased its holdings, acquiring 654,826 shares in Q1 2025, valued at roughly $6.6 million, making it their fourth-largest position. The general public, comprising individual investors, accounts for about 17% of the ownership. These ownership dynamics are influenced by strategic acquisitions, such as the integration of RITA Medical Systems in 2007 and the acquisition of Navilyst Medical in 2012, which significantly expanded the company's market presence and product offerings, impacting its overall company structure ownership.

Understanding AngioDynamics' Stakeholders

AngioDynamics' ownership is heavily concentrated among institutional investors, indicating strong professional management of its stock. Understanding these key stakeholders is crucial for assessing the company's stability and strategic direction.

• Institutional investors hold the majority of AngioDynamics stock, approximately 89.43% as of July 2025.
• BlackRock, Inc. is a significant shareholder, owning about 11% of outstanding shares.
• The Vanguard Group, Inc. and Systematic Financial Management LP are also major institutional holders.
• Millennium Management LLC and affiliates hold a passive stake of around 5.2-5.3%.
• The general public owns approximately 17% of AngioDynamics stock.
• Strategic acquisitions have shaped the company's market position and indirectly its ownership landscape.
• For insights into how the company generates revenue, explore the Revenue Streams & Business Model of AngioDynamics.

AngioDynamics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The AngioDynamics Board of Directors is responsible for the company's strategic direction and oversight. As of recent filings, key members include President and CEO Jim Clemmer, Eileen O. Auen, Howard W. Donnelly, Jan Stern Reed, and Karen Licitra. These directors often chair important committees such as Audit, Compensation, and Nominating, Compliance, and Corporate Governance.

Voting power at AngioDynamics is structured such that directors are elected by a plurality of votes cast at the Annual Meeting. This means the candidates with the most votes win, irrespective of achieving a majority. Shareholders provide voting instructions for non-routine matters like director elections and executive compensation votes. If shares are held in 'street name' and no instructions are given, those shares will not be voted on these specific issues. There is no indication of dual-class shares or other mechanisms that grant disproportionate voting control to any single entity or individual beyond standard share ownership. Further details on corporate governance and board matters are available through the company's investor relations channels.

Understanding AngioDynamics Board Structure

The AngioDynamics board ensures effective corporate governance. Key committees manage critical areas of the business.

• Directors elected by plurality of votes cast.
• Shareholder instructions vital for non-routine matters.
• No evidence of preferential voting structures.
• Board committees oversee compensation, audit, and governance.

AngioDynamics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, AngioDynamics has undergone a significant strategic shift, focusing on growth and technology. This transformation has naturally influenced its ownership trends, with institutional investors continuing to play a dominant role in who owns AngioDynamics.

AngioDynamics' strategic repositioning has been marked by key divestitures and a concentrated focus on high-growth technology platforms. This approach aims to enhance the company's market position and appeal to investors seeking exposure to innovative medical technologies. The company's financial performance and ongoing clinical developments further shape its ownership landscape, with institutional investors demonstrating sustained interest.

Portfolio Refinement

The divestiture of non-core assets, such as the Dialysis and BioSentry businesses in June 2023, and the PICC and Midline product portfolios in February 2024, has streamlined AngioDynamics' operations. This strategic move is designed to sharpen the company's focus on its most promising growth avenues.

Focus on High-Growth Technologies

AngioDynamics is prioritizing its advanced technology platforms, including the Auryon Atherectomy laser and Mechanical Thrombectomy products like AngioVac and AlphaVac. These areas are showing robust growth, with Auryon sales up by 19.7% and Mechanical Thrombectomy revenue increasing by 44.7% in fiscal year 2025.

Dominance of Institutional Ownership

As of July 2025, institutional investors hold approximately 89.43% of AngioDynamics' stock. This significant institutional backing underscores the confidence major investment firms have in the company's strategic direction and future prospects.

Financial Performance and Expansion

For fiscal year 2025, AngioDynamics reported net sales of $292.7 million, an 8.1% increase year-over-year. The Med Tech segment saw a 19.5% growth in net sales. The company's ongoing Growth Strategy of AngioDynamics is supported by positive clinical trial outcomes and regulatory milestones, such as the CE Mark approval for the AlphaVac F1885 System in May 2024.

AngioDynamics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔